Tag #Orforglipron

Showing 1 to 4 of 4 results

elmundo.es

🌐 85% Global Worthiness

Sep 18, 10:19

Oral Medication Shows Significant Weight Loss in Obesity Treatment

A phase 3 clinical trial involving 3,100 obese individuals across nine countries demonstrated that orforglipron, a novel oral medication targeting the GLP-1 receptor, resulted in an average 11.2% weight loss, primarily fat mass, and improved cardiovascular risk factors.

Oral Medication Shows Significant Weight Loss in Obesity Treatment

A phase 3 clinical trial involving 3,100 obese individuals across nine countries demonstrated that orforglipron, a novel oral medication targeting the GLP-1 receptor, resulted in an average 11.2% weight loss, primarily fat mass, and improved cardiovascular risk factors.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the broader implications of this research for obesity treatment and future directions?

The successful development of an effective oral GLP-1 receptor agonist represents a significant advancement in obesity treatment, potentially increasing accessibility and improving patient adherence. Further research should focus on long-term effects and the integration of orforglipron into comprehensive weight management programs.

zeit.de

🌐 85% Global Worthiness

Aug 8, 16:18

Eli Lilly's Orforglipron Shows Promise in Weight Loss Trial

Eli Lilly's Phase 3 trial of Orforglipron, an oral GLP-1 receptor agonist for weight loss, showed a 12.4% average weight loss in obese adults after 72 weeks, prompting plans for FDA approval by year's end; however, experts voice concerns about the yo-yo effect and lack of comparison to effective non...

Eli Lilly's Orforglipron Shows Promise in Weight Loss Trial

Eli Lilly's Phase 3 trial of Orforglipron, an oral GLP-1 receptor agonist for weight loss, showed a 12.4% average weight loss in obese adults after 72 weeks, prompting plans for FDA approval by year's end; however, experts voice concerns about the yo-yo effect and lack of comparison to effective non...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of Eli Lilly's successful Phase 3 trial for Orforglipron, and what are its immediate implications for weight management?

Eli Lilly's Orforglipron, a new oral GLP-1 receptor agonist, showed a 12.4% average weight loss in obese adults over 72 weeks in a Phase 3 trial, compared to 0.9% in the placebo group. The company plans to seek FDA approval by year's end, offering an alternative to injectable treatments. Common side effects included nausea, constipation, diarrhea, and vomiting.

theguardian.com

🌐 85% Global Worthiness

Sep 17, 01:17

Orforglipron: A New Daily Pill for Weight Loss Shows Promising Results

A 72-week trial of 3,127 obese adults found that orforglipron, a new daily weight-loss pill, led to significant weight loss, with 18.4% of those on the highest dose losing 20% or more of their body weight.

Orforglipron: A New Daily Pill for Weight Loss Shows Promising Results

A 72-week trial of 3,127 obese adults found that orforglipron, a new daily weight-loss pill, led to significant weight loss, with 18.4% of those on the highest dose losing 20% or more of their body weight.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential implications and future considerations regarding orforglipron?

Orforglipron's potential approval by the FDA and other regulatory bodies could greatly expand access to effective weight-loss treatment for millions. However, longer-term studies are necessary to assess the long-term effects and potential side effects, ensuring its safety and efficacy over extended periods.

us.cnn.com

🌐 85% Global Worthiness

Aug 7, 16:17

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly announced positive Phase 3 trial results for its oral GLP-1 obesity drug, orforglipron, showing a 12.4% average weight loss in 3,127 obese adults (excluding diabetics) after 72 weeks, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%, and fewer cardiovascula...

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly announced positive Phase 3 trial results for its oral GLP-1 obesity drug, orforglipron, showing a 12.4% average weight loss in 3,127 obese adults (excluding diabetics) after 72 weeks, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%, and fewer cardiovascula...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Eli Lilly's orforglipron Phase 3 trial results on obesity treatment?

In a Phase 3 trial, Eli Lilly's orforglipron, a once-daily oral GLP-1 pill, facilitated a 12.4% average weight reduction in obese adults over 72 weeks. This involved 3,127 participants with at least one weight-related health issue, excluding diabetes. The highest dose resulted in 59.6% achieving 10% weight loss and 39.6% achieving 15% weight loss.

Showing 1 to 4 of 4 results